Company intelligence / Profile preview

BIA Separations

Ajdovščina, Slovenia

Ownership: Private
Employees: ~120
Development stage: Other

Overview

BIA Separations does not have a drug pipeline but provides essential purification and analytical solutions that are used in both clinical and commercial production of cell and gene therapies, vaccines, and large biomolecules. It was acquired by Sartorius Stedim Biotech in November 2020 and now operates as Sartorius BIA Separations, continuing its leadership in monolith chromatography technology.

Modalities: Plasmid DNAmRNA-based drugsViral vectorsExosomesNanoparticle
Industry: Chemicals & Materials

Partnerships

Boehringer IngelheimAgilent TechnologiesShowa Denko K.K.JSR CorporationAveXis/Novartis

Beyond the preview

Go deeper on BIA Separations.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIA Separations.

Explore the full profile